Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : drives awareness and scientific discussion around lungworm -- Greater need to better understand the prevalence of lungworm in European countries / Scientific experts discuss prevention, infection, and persistence of lungworm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:25pm CET

Copenhagen (Denmark), October 5, 2017- Snails can explore the length of an average British garden in a single night, reaching a top speed of one meter per hour. They may seem like harmless creatures at first sight, but snails and slugs are quickly becoming a strong threat to the health and well-being of dogs. More and more dog owners have recently become aware of a disease which has been diagnosed more frequently over the last years throughout many European countries - Angiostrongylus vasorum (Lungworm/ French Heartworm).

Lungworm, or French Heartworm, is a disease spread by parasitic nematodes that can cause angiostrongylosis, a serious illness in dogs and other canine species. The parasite can be carried by slugs and snails and infect animals. The disease has not been shown to transmit to humans and is not considered a zoonotic disease. However, it was a topic of intense discussion and debate at the 42World Small Animal Veterinary Association (WSAVA) Congress in Copenhagen, Denmark.

The WSAVA hosts a veterinary congress once a year for companion animal veterinarians from across the globe. It is an internationally recognized veterinary congress with a scientific program.

Bayer Animal Health organized a continuing professional development for veterinarians and key opinion leaders entitled 'NEW UPDATES ON ANGIOSTRONGYLUS VASORUM IN EUROPE'. A panel of veterinary parasitology experts shared some insights on this topic.

Dr. Eric Morgan, MA, VetMB, PhD, BA, MRCVS UK, University of Bristol, Veterinary Parasitology and Ecology
'Lungworm infection used to be a rare disease in few European countries. However, we have had more cases recently in many European countriesso it is on the increase. For the UK and Germany there is now evidence that it is spreading. Spread of the disease is likely through infected dogs and foxes and via slugs and snails.'

Dr. Roland Schaper, Dr. med. vet, Bayer Animal Health GmbH, Global Veterinary Scientific Affairs Manager, Germany
'Treatment of an existing
A. vasoruminfection should be the last resort, due to the severity of the disease. Prevention of this potentially fatal disease with regular treatment is a good approach. But the best approach to avoid any parasite development completely is true infection prevention.'

While the lungworm is recognized as a major threat in the United Kingdom and the Nordics, it still seems to be underestimated in other European countries such as France, Germany and the Benelux. For the United Kingdom and Germany there is new evidence that it is spreading.

'This also demonstrates the importance of continuous training for veterinarians,' says Dr. Markus Edingloh, Global Head of Veterinary Scientific Affairs at Bayer Animal Health. 'Therefore, Bayer Animal Health is proud to support veterinarians with continuing professional development about the latest information and techniques. We want to emphasize the importance of fighting Angiostrongylus vasorumand draw attention to the fact that prevention plays an essential role in keeping our animals healthy.'

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.

Bayer AG published this content on 05 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 October 2017 10:24:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
02/16BAYER : fördert freiwilliges Mitarbeiter-Engagement seit zehn Jahren
PU
02/15BAYER : Researchers Submit Patent Application, "Antibody and Protein Formulation..
AQ
02/15BAYER : Recent Findings in Pesticides Described by Researchers from Bayer (Refin..
AQ
02/15BAYERNPV : Bayer receives first approval for Eylea in China
AQ
02/15BAYER : Syngenta aims to sell bonds within weeks, M&A important - CFO
RE
02/15BAYER : and Mitsui Chemicals Agro sign licence agreement for novel fungicide
PU
02/14BAYER : Gets FDA Warning Over Manufacturing Practices at German Site
DJ
02/14BAYER : gets FDA rebuke for drug production in Germany
RE
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
02/14BAYERNPV : Bayer - New data for aflibercept show prolonged injection intervals
AQ
More news
News from SeekingAlpha
02/16Tracking David Einhorn's Portfolio - Q4 2017 Update 
02/15Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q4 2017 Update 
02/14ROAD TO FINANCIAL INDEPENDENCE : My January 88-Stock Portfolio Review 
02/13Bayer sues Russian antitrust regulator in bid for more time in Monsanto case 
02/13YOUR DAILY PHARMA SCOOP : A Look At Celldex, BeiGene Data, Axovant Announces Cha.. 
Financials (€)
Sales 2017 35 346 M
EBIT 2017 7 428 M
Net income 2017 6 815 M
Debt 2017 8 806 M
Yield 2017 2,64%
P/E ratio 2017 13,63
P/E ratio 2018 18,28
EV / Sales 2017 2,55x
EV / Sales 2018 2,50x
Capitalization 81 487 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 121 €
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-6.36%100 998
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572